scispace - formally typeset
G

Glenn M. Chertow

Researcher at Stanford University

Publications -  830
Citations -  94517

Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.

Papers
More filters
Journal ArticleDOI

#2758 ambient heat exposure and estimated glomerular filtration rate trajectory: a post-hoc analysis of the dapa-ckd trial

TL;DR: The DAPA-CKD trial showed that higher ambient heat exposure is associated with a faster loss of kidney function in patients with established, all-cause, chronic kidney disease as discussed by the authors .
Posted ContentDOI

Use of wastewater metrics to track COVID-19 in the U.S.: a national time-series analysis over the first three quarters of 2022

TL;DR: In this article , the authors examined the performance of two wastewater metrics in predicting high case and hospitalization rates both before and after widespread use of at-home COVID-19 tests and concluded that the predictive capability of wastewater percentile declined over time (AUC 0.84 and 0.72 for cases for second and third quarters of 2022).
Journal ArticleDOI

Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism.

TL;DR: The broader Medicare dialysis bundle reimburses providers uniformly, even though patients treated more intensively for sHPT cost more to treat, and this flat payment schedule may encourage providers to avoid high-intensity patients or reduce their treatment intensity.
Journal ArticleDOI

Race and Place in ESKD

TL;DR: The authors focus on Black men, who experience markedly higher rates of ESKD than nonBlack men, particularly at younger ages, and highlight one element of place, the proportion of Black residents, which contributes to rates of death and hospitalization among Black men receiving hemodialysis.
Journal ArticleDOI

Population-Wide Screening for Chronic Kidney Disease

TL;DR: In this article , a cost-effectiveness analysis of using SGLT2 inhibitors to detect chronic kidney disease (CKD) in adults was conducted in the United States.